Physician profile
Rigoberto Barba
NPI 1043221781
$2,235.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $750 · 2021: $369.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $671.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $485.72 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $412.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $145.82 | 2019-2021 | |
| Pfizer INC. | $60.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $46.55 | 2021 | |
| Abbvie INC. | $39.09 | 2019-2021 | |
| Novo Nordisk INC | $37.70 | 2019 | |
| Mayne Pharma Commercial LLC | $36.91 | 2021 | |
| Allergan, INC. | $31.50 | 2019 | |
| Glaxosmithkline, LLC. | $24.20 | 2021 | |
| Janssen Scientific Affairs, LLC | $17.66 | 2019 | |
| Amgen INC. | $13.54 | 2019 | |
| Abbott Laboratories | $12.63 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $12.00 | 2021 | |
| Sanofi Pasteur INC. | $11.35 | 2019 | |
| Lilly USA, LLC | $11.13 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.06 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rigoberto Barba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.